Disulfiram combats cancer via crippling valosin-containing protein/p97 segregase adaptor NPL4

Nan Ding1,2, Qianzheng Zhu2,3

1CAS Key Laboratory of Heavy Ion Radiation Biology and Medicine, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China; 2Department of Radiology, 3James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA

Correspondence to: Qianzheng Zhu. Department of Radiology, The Ohio State University, 1024 Biomedical Research Tower, 460 W 12th Avenue, Columbus, OH 43210, USA. Email: zhu.49@osu.edu.

Provenance: This is an invited Editorial commissioned by Section Editor Dr. Chen Qian (Center for Inflammation & Epigenetics, Houston Methodist Hospital Research Institute, Houston, TX, USA).


doi: 10.21037/tcr.2018.03.33

View this article at: http://dx.doi.org/10.21037/tcr.2018.03.33

Disulfiram (DSF), also known as Antabuse, is a Food and Drug Administration (FDA)-approved drug, which has been used for anti-alcoholism in clinic for more than 60 years (1). DSF is a member of the dithiocarbamate (DTC) family, which comprises a broad class of molecules possessing an R1R2NC(S)SR3 functional group that gives the family the ability to complex metals and react with sulfhydryl groups. DSF was originally found to act as an irreversible inhibitor of aldehyde dehydrogenase (ALDH) for anti-alcoholism and is safe with no toxicity (2). Due to the discovery that DSF and its metabolites kill cancer cells and slow tumor growth in animal models and human patients (3,5), there has been an effort for repurposing this drug for cancer treatment (6–9). Several potential targets of DSF’s action, such as ALDH, NF-κB and proteasome, etc., were recently found (please see references therein) (10). It appears that DSF can act against a broad spectrum of malignancies, and, it can also target cancer cells with cancer stem cell-like properties. It has been known that the tumor cytotoxic activity of DSF is copper-dependent. The precise mechanisms of DSF’s anticancer activity, however, are still unknown. A recent work by Skrott et al. identified valosin-containing protein (VCP)/p97 segregase adaptor NLP4 as a new molecular target of DSF (11), providing a new rationale for clinical trials aiming at repurposing this old drug.

NPL4 is one of major substrate adaptors of VCP/p97 segregase, which is conserved from yeast to human. The hexameric structure with AAA-type ATPase activity (Figure 1), together with adaptors/cofactors capable of binding to ubiquitinated substrates, enables VCP/p97 segregase to impose conformational changes on substrate proteins, and, to pull the ubiquitinated proteins out of membranes, segregate them from their binding partners or extract them from chromatin (12). The cellular function of VCP/p97 segregase is mostly based on its critical role in the ubiquitin-proteasome system (UPS).

The UPS is responsible for degradation of most cellular proteins, and thereby plays a regulatory role in a wide range of cellular processes. Because of UPS’s essential role in protein homeostasis, the UPS has been considered as an important target for anticancer drug development. The UPS includes two distinct steps. First, the target proteins are labeled with a minimum four ubiquitin moieties through an E1-E2-E3 cascade enzymatic ubiquitination reaction. Second, the ubiquitin-conjugated target proteins are recognized, unfolded and degraded by 26S proteasome. For some of target proteins, it is necessary to be segregated from their binding partners or imbedded cellular structures by VCP/p97 segregase, which then presents the target proteins to proteasome for degradation.

It is now known that VCP/p97 plays a central role in governing various aspects of protein homeostasis and cellular stress responses (13), including endoplasmic reticulum-associated degradation (ERAD), ribosome-associated quality...
control, mitochondria-associated degradation (MAD), cytosol degradation and macrophage (12-14). Furthermore, the VCP/p97-mediated extraction is now established as an integral part in fundamental chromatin-related processes (15), such as DNA replication (16), DNA damage response (17), double-strand break repair (18,19), DNA cross-link repair (20) and nucleotide excision repair (21,22). These VCP/p97 functions provide a rational understanding of the diverse phenotypic feathers (Figure 1), as described by Skrott et al. (11), when NPL4 function is impaired or poisoned by DSF's metabolite, DTC-copper complex [bis(diethylthiocarbamate)-copper (CuET)].

As a member of the largest family of VCP/p97 substrate adapters characterized by ubiquitin regulatory X (UBX) and UBX-like (UBXL) domain (12), NPL4 contains a N-terminal UBXL domain, and additional NPL4 conserved
domain, C-terminal NPL4 zinc finger (NZF) domain as well as a putative zinc finger-NPL4 (ZF-NPL4) domain. The NZF of NPL4 protein is capable of binding to poly-ubiquitin, while both NPL4 conserved and ZF-NPL4 domains mediate the interaction with UDF1 (23). The NPL4-UDF1 complex binds to the amino-terminal (N-terminal) domain of VCP/p97, forming a VCP/p97-UDF1-NPL4 core complex, which works together with other adaptors to act in the UPS.

Given the critical function of VCP/p97-UDF1-NPL4 complex in the UPS, it is not a surprise that some CuET-induced phenotypic features share with proteasome inhibitors, including accumulation of cellular poly-ubiquitin conjugates, diminution of ubiquitin-histone (uH2A) due to ubiquitin stress, cytoplasmic accumulation of poly-ubiquitinated proteins. Notably, it was previously reported that DSF and/or its metabolite was able to directly inhibit proteasome activity (24). Nonetheless, Skrott et al. demonstrated that CuET can target NPL4 at much lower concentration, which does not significantly affect ubiquitin-independent 20S-proteasome-mediated degradation. CuET acts on NPL4 through interacting the ZF-NPL4 domain and immobilizes NPL4, resulting in prominent nuclear, and to lesser extent, cytoplasmic clustering of NPL4. Consequently, the immobilized NPL4 aggregates trigger heat-shock response (HSR) and endoplasmic reticulum (ER) stress/unfolded protein response (UPR), the distinctive features induced by CuET. The nuclear NPL4 clusters co-localize with small ubiquitin-like modifier (SUMO) 2/3, poly-ubiquitin (lysine 48) and Tar DNA-binding protein 43 (TDP-43), which are typical features of aggregated defective protein. Unusually, VCP/p97 but not NPL4-binding partner UDF1 co-localizes with nuclear NPL4 clusters. The ectopically expressed NPL4 (MUT)–GFP with mutated ZF-NPL4 domain similarly forms immobile nuclear clusters spontaneously in untreated cells, reminiscent of events upon CuET treatment. Another CuET-induced distinctive phenotype is HSR, a cellular response caused by aggregation of misfolded or damaged proteins. The CuET-induced HSR is accompanied by nuclear stress foci of heat shock factor 1 (HSF1) and heat shock protein 70 (HSP70) at NPL4 clustering sites. Skrott et al. further suggested that immobilized NPL4 proteins attract ubiquitinated proteins or proteins that subsequently become ubiquitinated and/or SUMOylated. Thus, CuET cripples NPL4 but perhaps keeps it with the capability of binding to some of its protein interactors or ubiquitinated proteins. The identities and the functions of ubiquitinated proteins associated with immobilized NPL4 are yet to be uncovered. Nevertheless, it is attempting to ask whether the homeostasis of these proteins is formerly regulated by VCP/p97-UDF1-NPL4 complex and UPS, or whether the immobilized NPL4 proteins, especially in nucleus, are associated with certain cellular processes.

The phenomena that the poly-ubiquitin conjugates, (SUMO) 2/3 and VCP/p97 accumulate at NPL4 clustering sites while uH2A is diminished due to ubiquitin stress suggests that both ubiquitination cascade and VCP/p97 are hijacked for aggregated defective proteins as a result of CuET-induced NPL4 clustering. It was previously reported that accumulation of poly-ubiquitin-conjugated polyglutamine disease protein aggregates, associated with Huntington’s disease, not only causes uH2A deubiquitination, nuclear ubiquitin depletion, but also results in a functional VCP/p97 deficiency due to the sequestering of VCP/p97 by poly-ubiquitin-conjugated polyglutamine disease proteins. Consequently, the functional VCP/p97 deficiency leads to impaired double-strand DNA break repair (25). Thus, another question raised by the CuET-induced phenotypic features is whether VCP/p97 and other ubiquitin adapters are sequestered by NPL4 aggregates? What are cellular proteins and functionalities, e.g., DNA repair, affected?

Another interesting phenomena described by Skrott et al. is the higher CuET concentration in cancer cells. It is previously documented that the DSF-copper complex is highly cytotoxic to cancer cells but not damage normal cells (10). The CuET enrichment in cancer cells may explain the selective cytotoxicity of DSF to cancer cells.

The findings by Skrott et al. as mentioned in above, offer a new rationale for repurposing DSF for cancer therapy. Since the VCP/p97 segregase complex is involved in a variety of cellular functions, the findings may open a wide window to gain better insight into how DSF may be used in clinical trials or translational studies in future (Figure 1). For example, tests of DSF as radiosensitizer can be based on the role of VCP/p97-UDF1-NPL4 in double-strand DNA break repair (17-19). Similarly, trials of combinational use of DSF with DNA-damage therapeutics such as platinum and Et-743 can be rationalized by the role of VCP/p97-UDF1-NPL4 in nucleotide excision repair (21,22) and DNA cross-link repair (20). Because VCP/p97-UDF1-NPL4 functions cooperatively with proteasome in UPS, examinations of
the synergistic anticancer effect of DSF, with inhibitors of proteasome, VCP/p97, deubiquitinating enzymes and even PARP, are expected to undertake. The more specific functions of VCP/p97-UFD1-NPL4 are emerging, the more tests of potential applications of DSF would be warranted in future clinical and translational studies.

Acknowledgements

**Funding:** Our work on VCP/p97's functionality in nucleotide excision repair was supported by National Institute of Health grants ES012991 (to Q Zhu).

Footnote

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

References

